BRIEF — Pelago pens new collaboration with AstraZeneca

Pelago Bioscience, a spin-out from Sweden’s Karolinska Institute, has entered into a new strategic research collaboration and license agreement with Anglo-Swedish pharma major AstraZeneca.

In the last two years, the companies have collaborated on numerous Cellular Thermal Shift Assay (CETSA) projects and produced several publications.

The new collaboration will allow for the further development of the CETSA method and expansion of its use within pre-clinical discovery at AstraZeneca, with a focus on its application in screening, safety assessment and translational sciences.

Steve Rees, vice president for discovery biology at AstraZeneca, said: “CETSA is an exciting technology that will allow us to examine the interaction between a drug candidate and its protein target within the cell. We are pleased to be exploring the potential of this platform in an open collaboration with the scientists at Pelago.”